Therapy Area topics
Cardiovascular
Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
Central Nervous System
Boehringer’s digital drive starts bearing fruit
Less than two years after setting up its BI X digital lab, Boehringer Ingelheim is ready to start clinical trials of a programme monitoring speech patterns to diagnose…
Upcoming events – pivotal readouts for Intra-Cellular and Myovant
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Diabetes
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Poxel tastes sweet success at last
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
Digital Health
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Oncology
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Respiratory
Savara hopes to take a leaf out of Insmed’s book
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
The bubble bursts for Proteostasis
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Circassia finds a second way to put investors’ money under threat
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Various
Big-bucks first quarter masks drop in deal volume
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
Another knock back for urea cycle disorders
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.